News
NETRF’s Commitment to Excellence in Research Funding
At NETRF, our mission is to fund research that holds promise for advancing the understanding and treatment of neuroendocrine neoplasms (NENs). This is a commitment
Retreatment Efficacy of 177Lu-DOTATATE: A U.S. Center’s Findings
Recent advancements have broadened the spectrum of treatments for advanced NETs, encompassing a range of therapies that include peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.
NETRF-funded Researchers Win Top Awards at ENETS
Four NETRF-funded researchers were recognized for excellence and received awards at the recent European Neuroendocrine Tumor Society (ENETS) annual meeting in Vienna, Austria. CEO Elyse
FDA Grants Breakthrough Designation to AlphaMedix for Advanced Neuroendocrine Tumor Treatment
The FDA has granted breakthrough therapy designation to AlphaMedixTM (212Pb-DOTAMTATE) for treating adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking it as the first targeted
“Kath Bowl 2024” Raises Awareness, Funds for the Katherine Mueller NET Research Fund
“Kath Bowl” is an annual event organized by Katherine Mueller’s husband, Matt. “We hold this event every year to celebrate Katherine’s heavenly birthday,” said Matt.
FDA Paves Way for New Liver Tumor Treatment with Histotripsy
The U.S. Food and Drug Administration recently authorized a new technology called histotripsy to treat tumors in the liver, including neuroendocrine tumors. The noninvasive Edison®
Understanding Survival Factors in Lung Neuroendocrine Tumors: Insights from the California Cancer Registry
In 2019, Claire Mulvey, MD, received a NETRF Mentored Research Award to study the trends in incidence and survival outcomes for lung NETs. The goal
2024 NETRF Research Grant Opportunities – Letters of Intent Due by March 18, 2024
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce its 2024 Request for Applications. We’re seeking transformative research proposals in basic, translational, and clinical
NETTER-2 Trial Shows Lutathera® as First-Line Treatment Significantly Reduces Disease Progression or Death
Lutathera®, when given with long-acting release octreotide, reduces the risk of disease progression or death in those with newly diagnosed Grade 2 and 3 advanced
NETRF Awards Eleven Research Grants to Study Neuroendocrine Cancer
U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)